Many heart transplant recipients experience declining kidney function following transplantation. We aimed to quantify change in kidney function in heart transplant recipients stratified by pre-transplant kidney function. A total of 230 adult heart transplant recipients between May 1, 2008, and December 31, 2014, were evaluated for up to 5 years post-transplant (median 1 year). Using 19 398 total estimated glomerular filtration rate (eGFR) assessments, we evaluated trends in eGFR in recipients with normal/near-normal (eGFR ≥45 mL/min/1.73 m 2 ) vs impaired (eGFR <45 mL/ min/1.73 m 2 ) kidney function and the likelihood of reaching an eGFR of 20 mL/ min/1.73 m 2 after heart transplant. Baseline characteristics were similar. Immediately following heart transplant, the impaired pre-transplant kidney function group showed a mean eGFR gain of 9.5 mL/min/1.73 m 2 (n = 193) vs a mean decline of 4.9 mL/ min/1.73 m 2 (n = 37) in the normal/near-normal group. Subsequent rates of eGFR decline were 2.2 mL/min/1.73 m 2 /y vs 2.9 mL/min/1.73 m 2 /y, respectively. The probability of reaching an eGFR of 20 mL/min/1.73 m 2 or less at 1, 5, and 10 years following heart transplant was 1%, 4%, and 30% in the impaired group, and <1%, <1%, and 10% in the normal/near-normal group. Estimates of expected recovery in kidney function and its decline over time will help inform decision making about kidney care after heart transplantation.
| BACKG ROU N D
There are over 5 million people in the United States living with heart failure, and the prevalence of chronic kidney disease (CKD) is quite high in this group-up to 50%, depending on how CKD is defined. 1 Chronic kidney disease in patients with heart failure is mostly caused by kidney hypoperfusion (from heart failure itself and/or from medications used to treat heart failure including diuretics and renin angiotensin-aldosterone system blockade); recurrent episodes of acute kidney injury; and comorbid conditions including diabetes, hypertension, and atherosclerotic disease. 2, 3 In a select group of patients with advanced heart failure, heart transplantation is the treatment of choice.
Impaired kidney function before and after heart transplant is associated with a significant increase in the risk of death. Additionally, pre-transplant estimated glomerular filtration rate (eGFR) is independently associated with mortality in both the short-and longterm. [2] [3] [4] [5] [6] [7] An eGFR below 40 mL/min/1.73 m 2 is considered a relative contraindication to heart transplantation unless combined heartkidney transplant is an option. 8 Kidney function in patients awaiting heart transplant is dynamic, particularly in the peri-operative phase, which adds to the uncertainty of dual-organ allocation. In patients whose kidney disease is primarily hemodynamically driven, heartonly transplant may result in recovery of kidney function. For patients with moderate to severe CKD from intrinsic kidney disease, combined heart-kidney transplant may be necessary. 9 Heart and kidney transplant providers face the challenge of allocating a scarce resource with limited evidence to inform the decision of heart-only vs combined heart-kidney transplantation.
The extent to which impaired kidney function is reversible with improved renal perfusion after successful heart transplantation varies from patient to patient, and the degree of reversibility is difficult to assess during the peri-operative period. However, CKD after heart transplantation is common, and many patients may need counseling regarding progression of CKD. We therefore aimed to study longitudinal changes in kidney function among heart transplant recipients with and without impaired pre-transplant kidney function. We hypothesized that heart transplant recipients would experience improvement in kidney function following transplant and sought to quantify the degree of kidney function recovery. We also hypothesized that kidney function following heart transplant would decline steadily over time and sought to measure that rate stratified by pre-transplant kidney function. Understanding the expected changes in kidney function after heart transplantation could help inform decision making regarding kidney care after heart transplantation.
| ME THODS

| Study cohort
We used the Stanford Translational Research Database Environment (STRIDE) to identify a cohort of adults (age ≥18) who received heart transplants between May 1, 2008, and December 31, 2014. 10 We obtained demographic variables, information on comorbid conditions, and laboratory data using STRIDE queries. We excluded patients if they received prior or multiple organ transplants, were missing all serum creatinine determinations in the week prior to transplant (including the day of transplant), and/or were missing all serum creatinine determinations after transplant. We performed a detailed review of the electronic medical record of each patient to obtain additional transplant characteristics and populate missing laboratory data. We collected and managed study data using
REDCap electronic data capture tools hosted at the Stanford Center for Clinical Informatics. 
| Comparison groups
We defined impaired kidney function as having a baseline eGFR under 45 mL/min/1.73 m 2 in the week prior to heart transplant. We chose a cutoff point of eGFR <45 (stage 3b CKD or higher) as indicating impaired kidney function based on the low likelihood of misclassification at this level (relative to <60 mL/min/1.73 m 2 ) and because this population is considered to require more frequent monitoring by clinical practice guidelines, owing in part to higher rates of progression to advanced or end-stage kidney disease.
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| Outcomes
The primary outcome was eGFR trend over time in patients with normal or near-normal pre-transplant kidney function compared to those with impaired kidney function. As a secondary outcome, we examined the cumulative incidence of CKD by stage at 6 and 12 months.
We defined CKD stage according to KDIGO Lastly, we compared mortality rates in the two comparison groups.
| Immunosuppression
Patients received induction therapy with 500 mg of intravenous methylprednisolone when coming off bypass and 1 mg/kg (maximum dose: 125 mg) of rabbit antithymocyte globulin therapy on postoperative days 1, 2, and 3. The daily maintenance immunosuppressive regimen included tacrolimus (initiated at 0.5 mg twice daily) and mycophenolate mofetil (initiated at 1000 mg twice daily). Prednisone was initiated at 1 mg/kg/day and tapered to 0.5 mg/kg/day by month 6 and to 0.1 mg/kg/day by month 12. Dose adjustments were made as indicated by adverse effects and/or acute rejection. 17 We target a tacrolimus trough of 10-15 ng/mL in the first 6 months, [8] [9] [10] ng/mL between months 6-12, and 6-8 ng/mL thereafter.
| Statistical analysis
We analyzed our data using SAS statistical software, version 9.4 of the SAS System for Windows (SAS Institute Inc., Cary, NC, USA). were considered statistically significant.
We performed a longitudinal analysis of eGFR from 3 years prior to transplant to 5 years post-transplant excluding the month immediately post-transplant given day-to-day fluctuations in serum creatinine concentrations. We applied a log transformation to eGFR to normalize the distribution of the data. We assumed a linear mixed model with a multivariate normal distribution for log eGFR with an autoregressive correlation structure for the variance. This approach accounted for the within-subject correlation between measurements. The model included an indicator for transplant status (pre-vs post-transplant), time from transplant (treated as a continuous variable in days), and group (normal/near-normal vs impaired kidney function). We included a three-way interaction between time, transplant status, and group and all nested two-way interactions in the model. Predicted means and associated 95% confidence intervals of eGFR were plotted by group and days post-transplant. 
TA B L E 1 Baseline characteristics stratified by pre-transplant kidney function
Predicted values of eGFR were also tabulated for specific baseline values at 1 month, 1 year, 5 years, and 10 years post-transplant. We estimated the probability of having an eGFR below 10 and 20 mL/ min/1.73 m 2 using model parameter estimates. Distribution of log eGFR and residuals from the model were examined for normality.
Log eGFR was assumed to have a linear trend over time; however, we also examined nonlinear specifications for time. We found the results to be robust to the assumptions of the model. To explore the possible role of regression to the mean in our model, we applied the approach of Barnett et al. 18 In separate models, we estimated the cumulative incidence of CKD stage (1-2, 3a, 3b, 4, 5) at 6 and 12 months post-transplant adjusting for the competing risk of death. The cumulative incidence functions were estimated by nonparametric methods. We tested for differences between groups using Gray's test of homogeneity.
We created figures of the cumulative incidence of ESRD and death stratified by treatment group over the full 5 years of follow-up post-transplant.
| RE SULTS
Of the 251 records identified on STRIDE, 230 were included in the analysis. We excluded three previous transplant recipients, 16 with missing baseline creatinine, and two for inconsistent waitlist information. One hundred and ninety-three (84%) heart transplant recipients had normal or near-normal pre-transplant kidney function, and 37 (16%) had impaired pre-transplant kidney function.
The groups were reasonably well balanced with respect to baseline characteristics ( Table 1 ). The mean age was 51.4 and 58.9 years in the normal/near-normal and impaired kidney function groups, respectively. There were no statistically significant differences in race, marital status, smoking status, baseline comorbidities, total ischemic time, waitlist days, and calculated panel reactive or below (a point at which patients are eligible for kidney transplant listing) at 1, 5, and 10 years after heart transplant was <1%, 4%, and 30% in the impaired group and <1%, <1%, and 10% in the normal/ near-normal group. In Table 2 
| D ISCUSS I ON
Understanding longitudinal changes in kidney function following heart transplantation is important in optimizing kidney care after heart transplantation, timely referral for kidney transplantation and preparation for dialysis. Several studies have identified characteristics such as older age, female sex, hypertension, diabetes, pre-and early post-transplant kidney dysfunction as determinants of CKD following heart transplant. We demonstrate that heart-only transplant can initially result in improved kidney function in recipients with impaired pre-transplant kidney function, with an eGFR gain of 9.5 mL/min/1.73 m 2 in the first month. In contrast, rather than an improvement, a decline in eGFR of 4.9 mL/min/1.73 m 2 was seen in the group with normal/ near-normal kidney function. A possible explanation is that the hemodynamic improvement from a heart transplant exceeds the negative hemodynamic effects of calcineurin inhibitors in the impaired kidney function group, while the reverse may hold in the normal/near-normal group.
We also quantified the rate of kidney function decline following heart transplant. For our cohort, this was 2.9 mL/min/1.73 m 2 /y in the normal/near-normal group and 2.2 mL/min/1.73 m 2 /y in the impaired group. Table 2 In line with other studies, we demonstrate a 1 year high incidence of CKD stage 3b to 5 following heart transplant, which affected more than half of the patients who were transplanted with impaired kidney function. 6, 19 Patients with more advanced CKD (i.e., stage 3b and higher) have higher rates of morbidity and mortality in the years following transplantation. 3 Our study shows that 4% of the patients with impaired kidney function prior to heart trans- Patients with intrinsic kidney disease from diabetes, hypertension, and atherosclerotic vascular disease have an irreversible component to their kidney disease that will not be recovered by restoring hemodynamic function with heart transplantation. We found a similar prevalence of these risk factors in both groups, but our sample size was too small to permit a sub-analysis. We also evaluated the effect of VAD support in our preliminary analysis; however, our sample size precluded meaningful analysis (n = 4 for abnormal eGFR, n = 44
for normal eGFR).
Studies show that mortality is much higher in heart-only transplant recipients who become dialysis-dependent compared to a matched group of patients who are not on dialysis. In addition, heart-only transplant recipients on dialysis have significantly lower survival than a matched group of patients with end-stage-renal disease on dialysis. [2] [3] [4] 26 These data suggest that expedited kidney transplant or combined heart-kidney transplant might be preferred in candidates with advanced CKD. In our study, mortality was 6%
for near-normal and 11% in the impaired patients in the first year riving the greatest benefit from combined heart-kidney transplants.
While we did not aim to determine an exact eGFR threshold that derives benefit from combined heart-kidney transplant, we demonstrate that despite the initial gain in kidney function seen in heart transplant recipients with impaired kidney function, there is still significant decline in kidney function over time that should prompt careful consideration of dual-organ candidacy before proceeding with heart-only transplant.
Decisions regarding kidney allocation depend on the health providers' ability to predict recovery of kidney function following heart transplant as well as long-term kidney function trajectory. A recent publication by Goupil et al 29 highlights the difficulty in selecting patients for combined heart-kidney transplants. With studies showing good outcomes for heart-kidney transplants, [30] [31] [32] [33] [34] with the decreased rates of organ rejection in multi-organ transplant recipients (thought to be related to induction of partial immune tolerance, although the mechanisms are not completely understood), it is foreseeable that demand for kidneys in heart transplant candidates with impaired kidney function will continue to rise. In the over three decades since the first combined heart-kidney transplant, 35 there are no consensus guidelines to help cardiologists, cardiothoracic surgeons, or nephrologists select patients most likely to benefit from combined organ transplantation. Based on data from the Organ Procurement and Transplantation Network as of December 31, 2016, combined heart-kidney transplants represent less than 1% of heart transplants per year. However, the rates of heart-kidney transplants have increased by 400% in the past 15 years, while heart-only transplants have increased by 25% in the same time. We need more studies to quantify the change in kidney function with heart transplant alone to develop evidencebased guidelines.
| Limitations
Limitations of this study include a relatively small sample size, which precluded assessment of predictors of kidney function recovery in multivariate analyses. While Stanford is one of the largest heart transplant centers in the country, results may not be generalizable to the broader heart transplant population. As with all observational data, results may be influenced by variables we did not measure. For example, proteinuria, kidney size, and kidney biopsy data were not routinely assessed prior to transplantation and therefore were not available for analysis. There are also limitations in using creatininebased equations such as the MDRD-4 to calculate eGFR, our main measure of kidney function in this study. Of concern is the over- It is possible that there is some bias in the estimates due to regression to the mean, a common statistical problem among models with repeated observations. We estimated the bias due to RTM 18 to be approximately 1.07 units of eGFR, which would slightly attenuate the estimates of immediate gain/loss in eGFR post-transplant; however, this does not fully explain our results.
Determining true baseline kidney function is challenging given fluctuations in serum creatinine as mentioned; we used the lowest serum creatinine value in the week prior to transplant to calculate baseline eGFR. Our study could have been strengthened by assessing cardiac outcomes such as rejection, ejection fraction, and allograft vasculopathy; however, these data were not readily available.
We had data on all-cause but not cause-specific mortality; thus, we are unable to comment on death from cardiac causes.
| CON CLUS IONS
In this cohort, we determined that heart transplant recipients with impaired pre-transplant kidney function transiently gain 9.5 mL/ min/1.73 m 2 of eGFR with heart-only transplant. Heart transplant recipients with normal/near-normal pre-transplant kidney function experience a decline in kidney function of 4.9 mL/min/1.73 m 2 during this same period. Kidney function then declines steadily over time in both groups, albeit at a slightly faster rate in those with normal/near-normal pre-transplant kidney function. This information helps inform decision making for kidney care after heart transplantation. More studies in larger heart transplant populations are needed to refine these estimates.
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